Business
BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation
Images below confirm clinical responses seen in patients with metastatic orbital (eye), temporal ...
About this update from Briacell Therapeutics Corp
[{"type":"text","content":"BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation\nImages below confirm clinical responses seen in patients with metastatic orbital (eye), temporal (brain), liver, and spine lesions No Bria-IMT™ related discontinuations reported to dateBria-IMT regimen continues under Fast Track Designation from US FDA PHILADELPHIA and VANCOUVER, British Columbia, Jan. 28, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, releases new images highlighting resolution of metastatic breast cancer lesions in patients with orbital (eye), temporal lobe (brain), liver, and spinal involvement. Survival details on these and other select patients in its Phase 2 study, along with comparable populations, were previously reported. Table 1: Select Patients Patient/SubtypeMonths SurvivalAgeNumber of Prior RegimensCycles of Bria-IMT11-018/ER+/PR+/HER2+(Example 1 below)27668; including ENHERTU3515-005/ER+/PR+/HER2-(Example 2 below)27445615-006/ER+/PR-/HER2-(Example 3 below)25648; including TRODELVY4 Note that Trodelvy and Enhertu are antibody-drug conjugates recently approved for late-stage breast cancer. “The CD8 ImmunoPET images are remarkable, verifying the ability of the BriaCell treatment to activate CD8+ cytotoxic (“killer”) T cells and induce their infiltration into the cancerous tumors. This is key to the mechanism of action of the BriaCell approach and likely play a role in enhancing the long-term survival of patients even after they come off study,” stated Dr. William V. Williams, BriaCell’s President and CEO. Example 1: Patient 11-018 A 66-year-old woman with ER+/PR+/HER2+ metastatic breast cancer, heavily pretreated with 8 prior lines of therapy, including an antibody-drug conjugate (Enhertu), remains alive 27 months post-enrollment. At baseline, she presented with metastatic involvement of the right orbit (behind the eye), right temporal lobe of the brain and multiple skeletal sites. Following treatment, she achieved complete resolution of the temporal lobe metastasis, substantial improvement in the orbital lesion and stable disease in the bone. Sh...